Musculoskeletal complications and aromatase inhibitors in adjuvant breast cancer treatment

The use of aromatase inhibitors in postmenopausal patients with breast cancer have modified the pronostic and may prove to be the agents of choice in this setting. However this treatment is associated with an increased rate of short-term symptoms: articulary and muscle pain and long-term symptoms: bone loss and fractures. The decision making process is driven by the existence of these complication With the continuation of the life expectation, the prevention of the osseous iatrogenic complications must not be neglected in the care of these patients.